Clinical Trial Update: Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) [Phase 2]

View source ↗

Summary

Phase 2 trial results (EFFIKIR) evaluating an anti-KIR monoclonal antibody as maintenance therapy in adults with acute myeloid leukemia have been posted. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Anti-KIR monoclonal antibody (anti-KIR monoclonal antibody)

Snippet

Sponsor: Innate Pharma | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2019-02-08